This clinical practice guideline from the American College of cardiology (ACC) and American Heart Association (AHA) provides recommendations applicable to patients with or at risk of developing cardiovascular disease (CVD).
ACC / AHA guideline on the primary prevention of cardiovascular disease
College of Cardiology / American Heart Association Task Force on Clinical Practice Guidelines, 2019
This clinical practice guideline from the American College of cardiology (ACC) and American Heart Association (AHA) provides recommendations applicable to patients with or at risk of developing cardiovascular disease (CVD). The focus is on medical practice in the United States, but the guidelines also have global relevance.
The guideline discusses risk factors for CVD including lifestyle and diet, plus comorbid conditions such as diabetes and chronic kidney disease (CKD). Specifically related to point-of-care testing (POCT), it provides information on risk factor parameters that can be obtained via POCT, such as lipid panels (total cholesterol, low- and high-density lipoprotein and trigycerides) to guide treatment decisions, such as statin therapy. HbA1c and albumin-creatinine ratio (ACR) are also highlighted as risk assessment parameters for patients with diabetes at risk of CVD.
The guidelines can be accessed here.
＆复制; 2022 年雅培。版权所有。引用的所有商标均为雅培集团公司或其各自所有者的商标。
Kunihiro Matsushita, Josef Coresh, Yingying Sang, John Chalmers, Caroline Fox, Eliseo Guallar, Tazeen Jafar, Simerjot K Jassal, Gijs W D Landman, Paul Muntner, Paul Roderick, Toshimi Sairenchi, Ben Schöttker, Anoop Shankar, Michael Shlipak, Marcello Tonelli, Jonathan Townend, Arjan van Zuilen, Kazumasa Yamagishi, Kentaro Yamashita, Ron Gansevoort, Mark Sarnak, David G Warnock, Mark Woodward, Johan Ärnlöv, CKD Prognosis Consortium
Estimated glomerular filtration rate and albumin-to-creatinine ratio testing for cardiovascular risk assessmenten立即访问
Johan Sundström, Johan Bodegard, Andreas Bollmann, Marc G Vervloet, Patrick B Mark, Avraham Karasik, Tiago Taveira-Gomes, Manuel Botana, Kåre I Birkeland, Marcus Thuresson, Levy Jäger, Manish M Sood, Gijs VanPottelbergh, Navdeep Tangri; on behalf of the CaReMe CKD Investigators
Prevalence, outcomes and cost of chronic kidney diseaseen立即访问